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GENOTYPE-PHENOTYPE ANALYSIS OF 4q DELETION SYNDROME: PROPOSAL 
OF A CRITICAL REGION 
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ABSTRACT 
Chromosome 4q deletion syndrome (4q- syndrome) is a rare condition, with an estimated 
incidence of 1 in 100,000. Although variable, the clinical spectrum commonly includes 
craniofacial, developmental, digital, skeletal and cardiac involvement. Data on the genotype-
phenotype correlation within the 4q arm is limited. We present detailed clinical and genetic 
information by array CGH on twenty patients with 4q deletions.  We identified a patient who has 
only a ~ 465 kb deletion (186,770,069-187,234,800, hg18 coordinates) in 4q35.1 with all clinical 
features for 4q deletion syndrome except for developmental delay, suggesting that this is a 
critical region for this condition and a specific gene responsible for clefts and congenital heart 
defect resides in this region. Since the patients with terminal deletions all had cleft palate, our 
results provide further evidence that a gene associated with clefts is located on the terminal 
segment of 4q. By comparing and contrasting our patients’ genetic information and clinical 
features, we found significant genotype-phenotype correlations at a single gene level linking 
specific phenotypes to individual genes. Based on these data, we constructed a hypothetical 
partial phenotype-genotype map for chromosome 4q which includes BMP3, SEC31A, MAPK10, 
SPARCL1, DMP1, IBSP, PKD2, GRID2, PITX2, NEUROG2, ANK2, FGF2, HAND2 and DUX4 
genes.  
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INTRODUCTION 
The 4q deletion syndrome, also called 4q- syndrome, is a rare chromosomal disorder caused by 
interstitial and terminal deletions of the long arm of chromosome 4, with an estimated incidence 
of 1 in 100,000 [Strehle et al., 2001, Strehle et al., 2003]. The majority of deletions are de novo 
but approximately 14%, of cases result from unbalanced segregation of parental reciprocal 
translocations [Strehle et al., 2003]. The male to female ratio is ca. 1. 4q deletion syndrome is a 
distinct congenital malformation syndrome associated with clinical findings affecting multiple 
organs and systems including developmental delay, facial and digital dysmorphology, Pierre 
Robin sequence, abnormalities of the cardiovascular, musculoskeletal and gastrointestinal 
systems. A review of 101 patients with 4q deletion syndrome revealed craniofacial anomalies in 
almost all individuals. Additionally, 88% had digital anomalies, 54% had skeletal anomalies, and 
almost half had congenital heart disease (CHD) [Strehle et al., 2003]. Autistic spectrum disorder 
and attention deficit hyperactivity disorder are part of the behavioral phenotype in 4q deletion 
syndrome [Strehle et al., 2007]. Figure 1 shows a female infant with 4q deletion syndrome. 
Interstitial deletions have been associated with short limbs and small hands, Rieger syndrome 
and piebaldism [Strehle et al., 2003]. More distal deletions involving 4q34-q35 were associated 
with a lesser degree of characteristic features and cognitive impairment [Keeling et al., 2001; 
Kocks et al., 2002]. Satyr ears and hypoplastic fifth finger with a distinctive pointed nail were 
mainly found in terminal deletions involving 4q34 [Vogt et al., 2006].  Region 4q33 has been 
proposed as the critical region for 4q deletion syndrome [Keeling et al., 2001; Giuffre et al., 
2004], containing genes responsible for development of the left ulnar ray, central nervous system 
and cleft lip and palate. 
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The first review on 4q deletions including a clinical correlation study dates back to 1981 
[Mitchell et al.]. Since then, over 150 patients with 4q deletion syndrome have been reported in 
the literature [Lin et al., 1988; Strehle, 2011]. Many of these patients have been evaluated 
through traditional chromosome analysis with standard or high resolution banding only. 
Traditional cytogenetic studies such as high resolution chromosome banding will not detect a 
deletion less than 3-5 million base pairs, and exact breakpoints cannot be defined. Therefore, it is 
difficult to establish individual genotype-phenotype correlations. With the emergence of 
microarray-based comparative genomic hybridization (array CGH), the resolution for detecting 
deletions can reach the single-gene level. 
Recently, array CGH has been used to characterize patients with 4q deletions in an attempt to 
elucidate genotype-phenotype correlations [Quadrelli et al., 2007b; Sensi et al., 2008; Kitsiou-
Tzeli et al., 2008; Kaalund et al., 2008; Rossi et al., 2009; Hilhorst-Hofstee et al., 2009; Moreira 
et al., 2010; Chien et al., 2010; Al-Owain et al., 2010; Bonnet et al., 2010]. Previously published 
reports are limited to a small number of cases. For this study, we characterize 20 patients with 4q 
deletion syndrome. All patients were analyzed by array CGH. Significant correlations were 
found between deletions on the 4q arm and clinical signs and symptoms; they enabled us to 
propose genotype-phenotype correlations for a larger group of patients. 
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MATERIALS AND METHODS 
Patient recruitment. All patients were recruited under the Institutional Review Board (IRB) 
protocol approved by the human subject committee of the University of California, Irvine (UCI). 
Individuals with a deletion in the 4q region diagnosed by array CGH as described previously 
[Quadrelli et al. 2007a] were eligible to enroll. One group of patients was seen by our group at 
the University of California Irvine Medical Center (UCIMC). After consent was obtained, the 
patients were evaluated by our board certified clinical geneticists. A second group of patients 
was referred to us by their local physicians or geneticists. Medical records were obtained and 
reviewed.  
Array CGH. Oligonucleotide-based microarray analysis was performed on patients with a 
105K-feature whole-genome microarray (SignatureChip Oligo SolutionTM, custom-designed by 
Signature Genomics Laboratories, made by Agilent Technologies, Santa Clara, CA).  Microarray 
analysis was performed as previously described [Quadrelli et al., 2007a, Quadrelli et al., 2007b]  
Fluorescence in situ hybridization (FISH). All deletions determined to be abnormal by array 
CGH were visualized by metaphase FISH using Bacteria Artificial Chromosome (BAC) clones, 
as previously described [Traylor et al., 2009]. Parental blood samples, where available, were 
karyotyped and/or assayed with metaphase FISH. 
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RESULTS 
The clinical and molecular data for 20 patients were analyzed and summarized in Table I. The 
patients were numbered from 1 to 20 based on the location of the deletion, with number 1 closest 
to the centromere and number 20 closest to the telomere. Fourteen females and six males were 
enrolled in the study ranging from age 3 days to 33 years. Hypotonia was noted in ten patients 
(50%), cardiac involvement in nine (45%), developmental delay in eighteen (19%), and digital 
involvement in thirteen (65%) out of twenty patients. Thirty percent of patients had behavioral 
problems. The frequency and characteristics of clinical symptoms in our cohort was similar as 
previously reported [Strehle and Bantock, 2003] as illustrated in Table II, with a few new 
observations. Our cohort had a lower incidence of hearing and respiratory tract abnormalities 
(15% versus 37% and 32% respectively). A higher incidence of dentition abnormalities was 
reported (30% versus 18% previously). Parental chromosomes were available on nine patients 
and abnormal in four (44%  22%) which is higher than previously reported 14%  7% with 13 
abnormal parental chromosomes in a cohort of 90 [Strehle and Bantock, 2003].  
Figure 2 shows the region of the deletion for all 20 patients. The smallest deletion detected was 
160 KB (3 OMIM genes) and the largest deletion was 25.7 MB (45 OMIM genes) covering a 
region from 4q21.1 to 4q35. The clinical features shared by patient 1 and patient 2 include short 
stature, brachydactyly, hypotonia, movement disorder, developmental delay, absence of speech 
and incontinence. The clinical feature shared by patient 2 and 3 is epilepsy; an additional unique 
feature of patient 3 is unilateral polycystic kidney dysplasia. Interestingly, patient 5 was found to 
have a micropenis while patient 7 was diagnosed with Axenfeld-Rieger syndrome and glaucoma. 
The deletion in patient 6 is relatively small and has no overlap with any other patients. The 
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 	
phenotype of patient 6 includes developmental delay and speech delay, behavior problems, 
staring spells, a large tongue, a large head, asthma and possible overgrowth syndrome. 
The deletions in patients 17-20 overlap with the deletions in patients 13-16. Patients 18, 19 and 
20 all have abnormal teeth and finger/toe anomalies. Patients 17, 18 and 20 have a large tongue 
and congenital heart defects. Patients 17, 18 and 19 have developmental delay and speech delay. 
In addition, patients 17 and 20 both have cleft palate, upturned nose, hypotonia and 
gastroesophageal reflux. Patients 18 and 19 have growth deficiency or growth failure. Patients 18 
and 20 both have small hands and feet. Patient 19 and 20 both have frontal bossing, 
hypertelorism and cleft lip. 
The size of the deletion is largest in patients 13-16 and is progressively smaller in patients 17, 
18, 19, and 20 with each preceding patient covering the same deletion the later ones have. 
Therefore one might expect that the severity of the phenotypic abnormality would be greatest in 
patients 13-16 and would become progressively less severe in patients 17, 18, 19, and 20 and that 
each preceding patient’s features would include the same abnormal phenotype that the later one 
has. However, such correlations were not seen in our data. 
Most interestingly, Patient 20, who has only two genes deleted, PDLIM3 (PDZ and Lim Domain 
Protein 3) and TLR3 (Toll-Like Receptor 3), shows a variety of abnormal features that are 
difficult to explain by the two genes deleted. The only phenotype that presents in all other 
patients but not in Patient 20 is developmental and speech delay. However, since the patient was 
young (3 years old) at the time of evaluation and had multiple congenital anomalies including 
ventriculomegaly, it is very likely that she will have developmental delay later in life. It is also 
interesting to see that patients 13, 15, 17 and 20 all have cleft palate. Although a specific gene, 
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which could be responsible for clefts or influence palate development, could not be located, it is 
most likely to reside in 4q33-4q35.1.  
DISCUSSION 
In this study, we recruited 20 individuals with 4q deletion characterized by array CGH. Clinical 
phenotypes were also intensively evaluated. The clinical characteristics of our patients are 
compatible with the 101 patients reviewed by Strehle and Bantock [2003]. The primary 
abnormalities in this group of patients are craniofacial malformation, developmental delay, and 
digital, skeletal, and congenital heart defects. Array CGH is an emerging technology for 
characterizing patients with 4q deletion syndrome in an attempt to elucidate genotype-phenotype 
correlations [Quadrelli et al., 2007b]. Recently, Li’s group reported two patients with 4q 
deletions. In one of their cases, they found a 2.5 Mb duplication and a 12.6 Mb deletion in 
4q34.1. In the other case, a patient presented with history of Pierre-Robin sequence, cardiac 
malformation, and learning disability. This patient had a de novo deletion of 16.4 Mb in 4q34.1 
to 4q35.2 [Rossi et al., 2009]. The authors suggested that a 4 Mb region on chromosome 4q is 
harboring a candidate gene for Pierre-Robin sequence. 
Molecular genetic information for patients with chromosome 4 deletions is limited due to the 
small number of published cases. The combination of the availability of the human genome 
sequence and the emergence of high-density oligonucleotide array CGH allowed us to study 
genotype-phenotype correlations at the single gene level in twenty patients with 4q deletion 
syndrome. 
By comparing and contrasting the phenotypes and genotypes, the study suggests the following: 
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Interstitial Deletions 
Among the genes deleted in patients 1 and 2, Bone Morphogenetic Protein 3 (BMP3) gene is a 
member of the transforming growth factor beta family. Studies suggest that BMP3 regulates 
cartilage cell proliferation [Gamer et al., 2008]. Therefore, deletion of BMP3 may be associated 
with short stature and the skeletal anomalies shared by these patients. Sec31a is also in this 
region and is a component of the Coat Protein Complex II (COPII) dependent collagen secretion. 
It has previously been shown to be important for normal craniofacial development [Stagg et al., 
2008], therefore this gene may be associated with the abnormal craniofacial development shared 
by these two patients. In contrast with patient 2, patient 1 also has abnormal teeth. This suggests 
that Galactokinase 2 (GK2) specifically deleted in patient 1 may be associated with abnormal 
teeth and other specific phenotypes. Similarly, the genes deleted specifically in patient 2 may be 
responsible for his specific phenotypes, including macrocephaly and hypoplastic suborbital 
region, short palpebral fissures and other craniofacial features. With this approach, we found: 
Mitogen-Activated Protein Kinase 10 (MAPK10) plays an important role in neuronal apoptosis. 
Disruption of this gene in a de novo balanced translocation has been reported, associated with a 
patient with pharmacologically resistant epileptic encephalopathy [Shoichet et al., 2006]. 
Therefore, the deletion of MAPK10 may be associated with the finding of the epilepsy in patients 
2 and 3.  
Polycystin-2 (PKD2) encodes the membrane protein polycystin 2. This protein affects renal 
tubule development, morphology, and function. It is able to modulate intracellular calcium and 
other signal transduction pathways [Wu et al., 2002]. The protein interacts with polycystin 1. 
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Heterozygous mutations in both polycystin-1 and polycystin-2 are associated with autosomal 
dominant polycystic kidney disease [Harris et al., 2009; Mochizuki et al., 1996]. Patient 3 has 
unilateral polycystic dysplasia indicating that haploinsufficiency of PKD2 may be responsible 
for the cystic renal anomalies. 
Dentin Matrix Acidic Phosphorprotein 1 (DMP1) is an extracellular matrix protein. Mutations of 
the DMP1 gene are associated with autosomal recessive hypophosphatemia, a disease that 
manifests as rickets and osteomalacia [Feng et al., 2006]. Deletion of DMP1 in mice results in 
decreased bone matrix development. However, carriers do not show clinical/biochemical 
evidence of the disease. Therefore, whether deletions of DMP1 in patients 3 and 4 are associated 
with the growth deficiency in these two patients is yet undetermined.  
Integrin-Binding Sialoprotein (IBSP) is also a bone matrix protein. Deletion of the IBSP gene 
could also play an important role in the differentiation of the osteoblast and development of the 
bone matrix [Ogata 2008]. Therefore, deletion of IBSP may be associated with the growth 
deficiency in these two patients. 
Tachykinin receptor 3 (TACR3) is deleted in patient 5 but not in patient 4. This gene encodes a 
receptor for tachykinin neurokinin 3, also referred to as neurokinin B. Homozygous mutations of 
TACR3 have been associated with congenital gonadotrophin deficiency and puberty failure 
[Topaloglu et al., 2009]. Therefore, a deletion of TACR3 may be associated with the micropenis 
and small testes in patient 5. 
The 160 kb deletion in patient 6 has no overlap with any other patients and covers a total of 3 
genes listed in the OMIM) database: 3'-phosphoadenosine 5'-phosphosulfate synthase 1 
(PAPSS1) Sphingomyelin synthase 2 (SGMS2) and Cytochrome P450, family 2, subfamily U, 
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Polypeptide 1 (CYP2U). Haploinsufficiency of one or more of these genes may be related to the 
phenotype in this patient.  
PAPSS 1 is the sulfate donor co-substrate for sulfotransferase (SULT) enzymes [Xu et al., 2000]. 
SULTs catalyze the sulfate conjugation of many endogenous and exogenous compounds, 
including drugs and other xenobiotics. In humans, PAPS is synthesized by two isoforms, 
PAPSS1 and PAPSS2. In brain and skin, PAPSS1 is the major expressed isoform 
[Venkatachalam, 2003]. PAPSS1 is implicated to be a candidate hepatocellular carcinoma-
susceptibility gene in hepatitis B carriers [Shih et al. 2009]. The effect of hemizygosity for 
PAPSS1 on this patient’s phenotype is not clear. 
The protein encoded by SGMS2 (Sphingomyelin Synthase 2) is an enzyme that catalyzes 
sphingomyelin (SM) biosynthesis. SM is a major component of cell and Golgi membranes. 
Experiments by Ding et al. [2008] indicated that SGMS2 is a key factor in the control of SM and 
diacylglycerol levels within the cell and thus influences lipopolysaccharide-mediated apoptosis. 
The effect of hemizygosity for SGMS2 on this patient’s phenotype is unclear. 
Lastly, Cytochrome P450, Family 2, Subfamily U, Polypeptide 2 (CYP2U1) encodes a member 
of the cytochrome P450 superfamily of enzymes. This enzym  is a hydroxylase that metabolizes 
arachidonic acid, docosahexaenoic acid, and other long chain fatty acids. Long chain fatty acids 
have recently emerged as critical signaling molecules in neuronal, cardiovascular and renal 
processes. Chuang and others postulate that CYP2U1 plays an important physiological role in 
fatty acid signaling processes in both cerebellum and thymus, and therefore it may play a role in 
brain and immune functions (Chuang et al., 2004).  
The deleted regions in patients 7-10 overlap and have many genes in common. The genes that 
are deleted in these four patients are Traf-interacting protein with Forkhead-associated domain 
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(TIFA), Alpha-kinase 1 (ALPK1), Neurogenin-2 (NEUROG2), La Ribonucleoprotein domain 
family, member 7 (LARP7) and Ankyrin 2 (ANK2).  There are no obvious clinical features shared 
by these patients except for developmental delay.  Among the deleted genes, NEUROG2 is of 
particular interest. NEUROG2 is a member of the neurogenin subfamily of basic helix-loop-helix 
transcription factor genes that play an important role in neurogenesis from migratory neural crest 
cells. Heng et al. [2008] demonstrated that NEUROG2, which controls neurogenesis in the 
embryonic cortex, directly induces the expression of the small GTP-binding protein Rnd2 in 
newly generated mouse cortical neurons before they initiate migration. Thus, deletion of this 
gene may be associated with neurological findings in some of these patients. 
ANK2 encodes a member of the ankyrin family of proteins that link the integral membrane 
proteins to the underlying spectrin-actin cytoskeleton. Ankyrins play key roles in activities such 
as cell motility, activation, proliferation, contact and the maintenance of specialized membrane 
domains. The protein encoded by this gene is required for targeting and stability of Na/Ca 
exchanger 1 in cardiomyocytes. A loss-of-function (E1425G) mutation in ANK2 causes 
dominantly inherited type 4 long-QT cardiac arrhythmia in humans [Mohler et al., 2003], 
suggesting that the patients with deletion of ANK2 should be examined for arrhythmia. 
Several genes of interest are found in the deletions carried by patient 7, 8 and 10 but not in 
patient 9. PRSS12 encodes a member of the neurotrypsin family of serine proteases. Mutations in 
neurotrypsin 12 are associated with autosomal recessive mental retardation [Molinari et al., 
2002]. Studies in Drosophila suggest that this neurotrypsin may be involved in structural 
reorganizations associated with learning and memory [Didelot et al., 2006]. Therefore, deletion 
of PRSS12 may affect learning in these patients.  
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Phosphodiesterase 5A (PDE5A) encodes for a phosphodiesterase that specifically hydrolyzes 
cGMP to 5'-GMP. It is involved in the regulation of intracellular concentrations of cyclic 
nucleotides and is important for smooth muscle relaxation in the cardiovascular system [Sebkhi 
et al., 2003]. The effect of hemizygosity for PDE5A on these patient phenotypes is not clear, but 
it is possible that the deletion is relevant for the cardiovascular findings in these patients. 
Lastly, the protein encoded by FGF2 is a member of the fibroblast growth factor (FGF) family. 
FGF2 is a wide-spectrum mitogenic, angiogenic, and neurotrophic factor that is expressed at low 
levels in many tissues and cell types and reaches high concentrations in brain and pituitary. It has 
been implicated in diverse biological processes such as limb and nervous system development, 
wound healing, and tumor growth. The study of Ortega et al. showed that FGF2 homozygous 
knockout mice had abnormalities in the cytoarchitecture of the neocortex, most pronounced in 
the frontal motor-sensory area [Ortega et al., 1998]. Dono et al. [1998] established in their study 
that FGF2 participates in controlling fates, migration, and differentiation of neuronal cells, 
whereas it is not essential for their proliferation. The homozygous knockout mouse model by 
Montero et al. revealed that FGF2 helps determine bone mass as well as bone formation 
[Montero et al., 2000]. Using FGF2-deficient and wild type cardiomyocyte precursor cells from 
neonatal mouse hearts, Rosenblatt-Velin and colleagues proposed that cardiogenic differentiation 
depends on FGF2 [Rosenblatt-Velin et al., 2005]. Although heterozygous mutations in FGF2 
have not been fully explored, deletion of FGF2 may have an impact on some of the central 
nervous system, limb or cardiac abnormalities in patients 7, 8 and 10. 
The features that were found only in patient 7 (but not in patients 8-10) include Axenfeld-Rieger 
syndrome, hearing loss/impairment, short nose and ventricular septal defect. Among the genes 
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deleted in patient 7 but not in Patient 8-10 is Paired-Like Homeodomain Transcription Factor 2 
(PITX2) which encodes a member of the RIEG/PITX homeobox family. This protein is involved 
in the development of the eye, teeth and abdominal organs and acts as a transcriptional regulator 
involved in basal and hormone-regulated activity of prolactin. Mutations in this gene are 
associated with the Axenfeld-Rieger syndrome, iridogoniodysgenesis syndrome, and sporadic 
cases of Peter’s anomaly. Axenfeld-Rieger syndrome results in abnormal development of the 
anterior segment of the eye and results in blindness from glaucoma in approximately 50% of 
affected individuals (Fitch et al., 1978).  Deletion of PITX2 explains the glaucoma and Axenfeld-
Rieger syndrome present in patient 7.  
In contrast to patient 10, patient 11 has a deletion of PCDH10, which belongs to the 
protocadherin gene family, a subfamily of the cadherin superfamily. The gene encodes a 
cadherin-related neuronal receptor thought to play a role in the establishment and function of 
specific cell-cell connections in the brain [Kim et al., 2007]. PCDH18, deleted next to PCDH10, 
shares a similar function. Thus, the deletion of PCDH10 and PCDH18 may be associated with 
the neurological findings in patient 11. 
The deletion in patient 12 has no overlap with any of the other patients. The phenotype of patient 
12 includes large head, frontal bossing, maxillary hypoplasia, short saddle nose, bilateral 
postaxial polydactyly, clinodactyly of toes, short stature, poor weight gain, speech delay, 
learning difficulties, hyperactivity, oppositional behavior, cryptorchidism, seizures and severe 
ichthyosis. The 2.13 Mb deletion on chromosome 4q includes eight OMIM genes. Among them, 
HHIP (hedgehog interacting protein) encodes a protein similar to the mouse hedgehog-
interacting protein, a regulatory component of the hedgehog signaling pathway. Members of the 
hedgehog family are evolutionarily conserved proteins, which are involved in many fundamental 
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processes in embryonic development, including anteroposterior patterns of limbs and regulation 
of left-right asymmetry. It has been reported that heterozygous mutations in Indian hedgehog 
(IHH) result in brachydactyly type 1 [Gao et al., 2009]. Thus, the deletion of HHIP could 
potentially be associated with the digital anomalies in this patient.  
Another gene of interest in patient 12 is SMAD1. SMAD1 mediates the signals of the bone 
morphogenetic proteins (BMPs), which are involved in a range of biological activities including 
cell growth, apoptosis, morphogenesis, development and immune responses [Tsuchida et al., 
2008]. This protein can be phosphorylated and activated by the BMP receptor kinase. The 
phosphorylated form of this protein forms a complex with SMAD4, which is important for its 
function in the transcription regulation.  The clinical significance of heterozygosity for SMAD1 
has not been reported. A literature review of the other deleted genes on chromosome 4q did not 
reveal any likely association between those genes and the specific phenotype in patient 12. This 
patient also has a partial deletion of the X chromosome. Among the genes deleted on 
chromosome X, the deletion of STS (Steroid sulfatase) is known to cause X-linked ichthyosis 
(XLI). This explains the presence of severe ichthyosis in this patient. 
Terminal Deletions 
Patient 15 has a terminal 4q deletion and an additional chromosome abnormality; the 7 MB 
duplication on chromosome 20p includes a total of 55 OMIM genes. Among them, one gene of 
interest is TMC2. The specific function of this gene is unknown; however, expression in the 
inner ear suggests that it may be crucial for normal auditory function. It has been reported to be 
associated with autosomal recessive nonsyndromic hearing impairment [Tlili et al., 2008]. The 
effect of duplication for TMC2 on this patient’s phenotype is not clear, but it is possible that the 
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duplication is relevant for the conductive hearing loss in patient 15. Literature review of the other 
duplicated genes does not reveal any likely association between those genes and the specific 
phenotype in patient 15 and patient 18.  
The deleted regions in patients 13-16 have many genes in common. Patients 13-16 all have 
congenital cardiac defects, finger/toe anomaly, developmental delay and speech delay. Among 
the genes that are deleted in patients 13-16 is HAND2. The protein is a basic helix-loop-helix 
family of transcription factor and expressed in the developing ventricular chambers and plays an 
essential role in cardiac morphogenesis, implicating them as mediators of congenital heart 
disease (RefSeq, 2009; Morikawa et al., 2008]. In addition, this transcription factor may also 
play a role in limb and branchial arch development [Liu et al., 2009]. The deletion of HAND2 
may explain why Patients 13-16 all have congenital cardiac defects.  
Vascular Endothelial Growth Factor C (VEGFC) encodes a platelet-derived growth 
factor/vascular endothelial growth factor, which is active in angiogenesis and endothelial cell 
growth.  Deletion of VEGFC may be associated with development of the glabellar hemangioma 
in patients 13 and 14. 
Critical Region 
SORBS2 which is partially deleted in patient 20 encodes a protein containing N-terminal Sorbin 
and a C-terminal SH3 domain. The protein is high expressed in epithelia and cardiac muscle 
tissue. It has been found that the gene product interacts with ARG and c-ABL proteins (Hand et 
al., 2005). High expression level in cardiac tissue suggests that this gene may play an important 
role in heart development and may potentially contribute to congenital heart disease in patients 
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with 4q deletion syndrome. Molecular tests in patients with congenital heart defects for 
mutations in the SORBS2 gene are in progress. 
Limitations 
The findings of this genotype-phenotype correlation study are interesting despite some 
limitations. Firstly, the sample size is relatively small and the number of patients with any 
specific locus deleted is limited. Our cohort included a wide range of genomic imbalances with 
different clinical presentations.  By increasing the sample size, we should be able to fill the gaps 
and increase the confidence in the genotype-phenotype correlations. We hope that the genotypes 
and phenotypes presented here will, in combination with future findings and case reports, allow a 
better comparison of patients and enhanced phenotype-genotype correlations. Additionally, some 
of the clinical features were extracted from the clinical report of a geneticist, instead of by 
completion of a specifically designed checklist. Therefore, some of the clinical features may 
have been missed or overlooked. Furthermore, some of our patients have other chromosomal 
rearrangements that complicate the analysis of a genotype-phenotype correlation. In future, we 
plan to recruit additional patients with 4q deletion syndrome and build a fine map of deletions, 
through which, using the same approach, we will be able to pinpoint important genes for the 
phenotypes observed in 4q deletion syndrome. This information should prove useful for 
developing a more specific management and treatment plan for an individual with 4q deletion 
syndrome, based on the location and gene contact of the deletion. 
Conclusions 
Our findings as summarized in Table III and Figure 3 suggest that haploinsufficiency of the 
genes in 4q deletion syndrome is associated with specific phenotypes.  In summary, 
haploinsuficiency of BMP3 on 4q21.21 may be associated with short stature and other skeletal 
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anomalies. The loss of SEC31A on 4q21.22 may affect normal craniofacial development. The 
deletion of MAPK10 on 4q21.3 may be an explanation for the neurological findings and epileptic 
activities in some 4q deletion patients. On 4q22.1, SPARCL1 may be associated with central 
nervous system development, while both DMP1 and IBSP genes may play an important role in 
growth. PKD2 on 4q22.1 is known to be associated with abnormal renal phenotypes. GRID2 
may be associated with neurological findings and wide-based gait. On 4q25, deletion of PITX2 is 
responsible for Axenfeld-Rieger syndrome, while NEUROG2 plays an important role in 
neurogenesis in the embryonic cortex. The deletion of ANK2 may be associated with cardiac 
arrhythmia, and the loss of FGF2 on 4q27 may be associated with some CNS or limb anomaly. 
In addition, HAND2 on terminal 4q plays an essential role in cardiac morphogenesis, and the 
deletion of this gene may result in congenital cardiac defects. Although none of our patients was 
reported to exhibit features of FSHD, DUX4 located on 4q35.2 is known to be associated with 
autosomal dominant FSHD.  However, the patients with 4q deletions do not show the typical 
clinical phenotype of this muscular dystrophy, suggesting that haploinsufficiency of DUX4 is not 
the causative mechanism in FSHD.  Recently, it was shown that specific single nucleotide 
polymorphisms (SNPs) in the chromosomal region distal to the last D4Z4 repeat play an 
important role in this condition [Lemmers et al., 2010].  Finally, since four of our patients with 
terminal deletions all had cleft palate, it is likely that a gene associated with clefts resides on the 
4q terminal region. 
In summary, the 4q deletion syndrome is characterized by mild facial and digital dysmorphisms, 
developmental delay, learning disability, growth deficiency, skeletal and heart defects, and 
neurological and behavioral abnormalities. This syndrome is unusual so far as it includes 
deletions along the whole long arm of chromosome 4. In this phenotype-genotype study we have 
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been able to associate clinical findings with gene deletions by array CGH, with 
haploinsufficiency being the proposed underlying mechanism. In particular, the chromosome 
band 4q35.1 appears to harbor essential genes that contribute to this condition, if they are 
missing or mutated. However, considering the example of developmental delay, which is 
universally present in 4q deletion syndrome, and indeed in most chromosome imbalances, other 
causative mechanisms such as epigenetic factors and gene dosage effects should be explored. 
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FIGURE AND TABLE LEGENDS 
Fig. 1. Six-month-old girl with terminal deletion 4q33. The clinical features include growth 
deficiency, cleft palate, cardiovascular malformations (ASD, VSD). Dysmorphic features include 
microcephaly, rounded facies, small eyes, broad nasal bridge, upturned nose, full cheeks, small 
mouth and chin, short neck and Pierre-Robin sequence. She also has developmental delay and 
hypotonia 
Fig. 2. Ideogram of the long arm of chromosome 4 depicting the position and size of each of the 
20 deletions described in this report 
Fig.3. Schematic representation of chromosome 4 with arrows indicating mapped and 
hypothetical genes that may contribute to the phenotype in patients with 4q deletion syndrome 
 Table I. Array CGH results and phenotypic characteristics of 20 patients with 4q deletion 
syndrome 
 
Table II. Comparison of the clinical characteristics found in this study with those of the 101 
patients reviewed by Strehle et al., 2003 
Table III. Deleted genes and their functions in patients with 4q deletion syndrome 
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Table II. Comparison of the clinical characteristics found in this study with those of the 
101 patients reviewed by Strehle et al., 2003 
 
Characteristics  Our study (%  C.I.) Review (%  C.I.) 
Sample size  n=20 n=101 
Male/Female Ratio 0.43 (6/14) 0.91 (48/53) 
   
Abnormal Parental Chromosomes 
  4   (44%  22%)1    13 (14%    7%)4 
Developmental Delay 18   (95%  10%)2   77 (94%    5%)5 
Growth Failure 
  9   (47%  21%)3    56 (60%  10%)6 
Craniofacial Anomalies 20   (100%    0%) 100 (99%    2%)  
Cleft Lip 
  2   (10%  13%) N/A 
Cleft Palate 
  5   (25%  19%)   37 (37%    9%) 
Central Nervous System Defects 
  8   (40%  21%)   34 (34%    9%) 
Ocular Defect 
  8   (40%  21%)   44 (44%  10%) 
Hearing Defect 
  3   (15%  16%)   16 (37%    9%)7 
Digital Anomalies 14   (70%  20%)   89 (88%    6%) 
Skeletal and Extremity Defects 10   (50%  22%)   54 (54%  10%) 
Muscular Defect 11   (55%  22%)   45 (45%  10%) 
Cardiovascular Defect 10   (50%  22%)   50 (50%  10%) 
Respiratory Tract Anomaly 
  3   (15%  16%)   32 (32%    9%) 
Dental Defect 
  6   (30%  20%)   18 (18%    7%) 
Gastrointestinal Tract Anomaly 
  8   (40%  21%)   40 (40%  10%) 
Endocrine Defect 
  3   (15%  16%)     6 (6%    5%) 
Renal and Urinary Anomalies 
  2   (10%  13%)   19 (19%    8%) 
Genital Anomaly 
  4   (20%  18%)   28 (28%    9%) 
Skin/Hair Defect 
  7   (35%  21%)   43 (43%  10%) 
Behavior problems 
  6   (30%  20%) N/A 
 
1
 Parental chromosomes available on 9 cases 
2
 Developmental history applicable on 19 cases 
3
 Growth history applicable on 19 cases 
4
 Parental chromosomes available on 90 cases 
5
 Developmental history applicable on 82 cases 
6
 Growth history applicable on 94 cases 
7 Hearing evaluation available on 43 cases 
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Table III. Deleted genes and their functions in patients with 4q deletion syndrome 
 
Patient Deleted gene Relevant Function Literature Phenotype 
1 and 2 Bone Morphogenetic 
Protein 3 (BMP3) 
Belongs to the transforming 
growth factor-beta superfamily 
of regulatory molecules.  
Regulates cartilage cell proliferation [Gamer 
et al., 2008]. 
Short stature and 
skeletal anomalies. 
1 and 2 Sec31a Component of the Coat Protein 
Complex II (COPII) dependent 
collagen secretion.  
Important for normal craniofacial 
development [Stagg et al., 2008]. 
Abnormal craniofacial 
development.  
2 and 3 Mitogen-Activated 
Protein Kinase 10 
(MAPK10) 
Important role in neuronal 
apoptosis. 
Disruption in a de novo balanced translocation 
was seen in a patient with pharmacologically 
resistant epileptic encephalopathy [Shoichet et 
al., 2006]. 
Epilepsy. 
3 Polycystin-2 (PKD2) Renal tubule development, 
morphology and function. 
Encodes membrane polycystin 
protein which interacts with 
polycistine 1. 
Modulates intracellular calcium and other 
signal transduction pathways [Wu et al., 
2002]. Heterozygous mutations in PKD1 and 
PKD2 are associated with AD polycystic 
disease kidney [Mochizuki et al., 1996; Harris 
et al., 2009]. 
Unilateral polycystic 
renal dysplasia. 
3 and 4 Dentin Matrix Acidic 
Phosphorprotein 1 
(DMP1) 
Extracellular matrix protein. Mutations in DMP1 are associated with AR 
hypophosphatemia characterized by rickets 
and osteomalacia [Feng et al., 2006]. Mice 
with a DMP1 deletion show decreased bone 
matrix development. Carriers do not show 
evidence of disease. 
Growth deficiency.  
3 and 4 Integrin-Binding 
Sialoprotein (IBSP) 
Bone matrix protein. Involved in differentiation of osteoblasts and 
bone matrix development [Ogata, 2008]. 
Growth deficiency. 
5 TachykininRreceptor 3 
(TACR3) 
Encodes a receptor for 
tachykinin neurokinin 3. 
 
Homozygous mutations are associated with 
congenital gonadotrophin deficiency and 
puberty failure [Topaloglu et al., 2009]. 
 
7-10 Neurogenin 2 
(NEUROG2) 
Member of neurogenin 
subfamily of basic helix-loop-
helix transcription factor genes. 
Plays an important role in 
neurogenesis from migratory 
neural crest cells. 
Controls neurogenesis in the embryonic cortex 
and induces expression of GTP-binding 
protein Rnd2 in newly generated mouse 
cortical neurons prior to migration [Heng et 
al., 2008]. 
Neurological findings 
(hypotonia, seizures, 
dystonia, delayed 
motor  development). 
7-10 Ankyrin 2(ANK2) Linking integral membrane 
proteins to the underlying 
spectrin-actin cytoskeleton. 
Plays key role in cell motility, 
activation, proliferation, contact 
and the maintenance of 
specialized membrane domains. 
Protein is required for targeting 
and stability of Na+/Ca2+ 
exchanger in cardiomyocytes. 
A loss-of-function mutation (E1425G) in 
ANK2 causes dominantly inherited type 4 
long-QT cardiac arrhythmia in humans 
[Mohler et al., 2003].  
Arrhythmia 
(screening of patients 
recommended). 
7, 8,10 Protease Serine, 12 
(PRSS12) 
Member of the neurotrypsin 
family of serine proteases. 
PRSS12 mutations are associated with AR 
mental retardation [Molinari et al., 2002]. 
Drosophila studies suggest involvement in 
structural reorganizations associated with 
learning and memory [Didelot et al., 2006]. 
Learning disability 
and developmental 
delay.  
7, 8,10 Phosphodiesterase 5A 
(PDE5A) 
Hydrolyzes cGMP to 5'-GMP.  Regulation of intracellular concentrations of 
cyclic nucleotides, important for smooth 
muscle relaxation in the cardiovascular system 
[Sebkhi et al., 2003]. 
Congenital heart 
defects (VSD). 
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7, 8,10 Fibroblast Growth 
Factor 2 (FGF2) 
A mitogenic, angiogenic, and 
neurotrophic factor expressed at 
low levels in many tissues and 
cell types; it reaches high 
concentrations in brain and 
pituitary gland. Implicated in 
diverse biological processes 
such as limb and nervous 
system development, wound 
healing, and tumor growth. 
Participates in controlling fate, migration, and 
differentiation of neuronal cells [Dono et al., 
1998]. Homozygous knockout mice had 
abnormalities in cytoarchitecture of the 
neocortex, most pronounced in the frontal 
motor-sensory area [Ortega et al., 1998]. 
FGF2 helps to determine bone mass as well as 
bone formation [Montero et al., 2000]. 
Controls cardiogenic differentiation 
[Rosenblatt-Velin et al., 2005]. 
May have an impact 
on CNS, limb and 
cardiovascular 
abnormalities.  
11 Protocadherin 10 and 
18 (PCDH10,  
PCDH18 
Encodes a cadherin-related 
neuronal receptor. 
Establishment and function of specific cell-
cell connections in the brain [Kim et al., 2007] 
Neurological findings 
(delayed motor 
development, 
hypotonia). 
12 Hedgehog  Interacting 
Protein (HHIP) 
Regulatory component of the 
hedgehog signaling pathway.  
Evolutionarily conserved 
protein, involved in many 
fundamental processes in 
embryonic development, 
including anteroposterior 
patterns of limbs and regulation 
of left-right asymmetry. 
Heterozygous mutations result in 
brachydactyly type 1 [Gao et al., 2009]. 
Digital anomalies 
(bilateral polydactyly, 
clinidactyly of toes). 
12 Steroid Sulfatase(STS) 
 (X chromosome) 
Membrane-bound microsomal 
enzyme, hydrolyzes several 3-
beta-hydroxysteroid sulfates a 
metabolic precursors for 
estrogens, androgens, and 
cholesterol.  
Causes X-linked ichthyosis  Severe ichthyosis.  
15 7 MB duplication on 
chromosome 20p 
Unknown function.  AR nonsyndromic hearing impairment [Tlili 
et al., 2008].  
May be relevant to 
conductive hearing 
loss. 
13-16 Heart And Neural Crest 
Derivatives expressed 2 
(HAND2) 
Basic helix-loop-helix family of 
transcription factors Expressed 
in the developing ventricular 
chambers.  
Essential role in cardiac morphogenesis; 
implicated  as mediators of congenital heart 
disease [Morikawa and Cserjesi, 2008]. May 
play a role in limb and branchial arch 
development [Liu et al., 2009]. 
Congenital heart 
defects (VSD, 
coarctation of aorta, 
cardiomegaly, 
Tetralogy of Fallot). 
13 and 
14 
Vascular Endothelial 
Growth Factor C 
(VEGFC) 
Platelet-derived growth 
factor/vascular endothelial 
growth factor; active in 
angiogenesis and endothelial 
cell growth. Osmosensitive, 
hypertonicity-driven gene; 
intimately involved in salt-
induced hypertension.  
VEGFC signaling in phagocytes is a major 
determinant of extracellular volume and blood 
pressure homeostasis [Machnik et al., 2009].  
Glabellar 
hemangioma. 
13-18 
and 20 
SORBS2 Sorbin and SH3 domain 
containing 2 protein present in 
epithelial and cardiac muscle 
cells. 
Adapter protein to assemble signaling 
complexes linking ABL kinases and actin 
cytoskeleton [Hand et al., 2005]. 
Clefts and congenital 
heart defects. 
AD, autosomal dominant; AR, autosomal recessive; CNS, central nervous system; VSD, ventricular septal defect. 
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